These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18759353)

  • 1. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism.
    Tinazzi M; Ottaviani S; Isaias IU; Pasquin I; Steinmayr M; Vampini C; Pilleri M; Moretto G; Fiaschi A; Smania N; Giorgetti P; Antonini A
    Mov Disord; 2008 Oct; 23(13):1825-9. PubMed ID: 18759353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.
    Lorberboym M; Treves TA; Melamed E; Lampl Y; Hellmann M; Djaldetti R
    Mov Disord; 2006 Apr; 21(4):510-4. PubMed ID: 16250023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study.
    Tinazzi M; Morgante F; Matinella A; Bovi T; Cannas A; Solla P; Marrosu F; Nicoletti A; Zappia M; Luca A; Di Stefano A; Morgante L; Pacchetti C; Minafra B; Sciarretta M; Dallocchio C; Rossi S; Ulivelli M; Ceravolo R; Frosini D; Cipriani A; Barbui C
    Schizophr Res; 2014 Feb; 152(2-3):344-9. PubMed ID: 24369987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.
    Tinazzi M; Antonini A; Bovi T; Pasquin I; Steinmayr M; Moretto G; Fiaschi A; Ottaviani S
    J Neurol; 2009 Jun; 256(6):910-5. PubMed ID: 19252795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinsonian axial signs in schizophrenia.
    Morgante F; Barbui C; Tinazzi M;
    Parkinsonism Relat Disord; 2017 Mar; 36():89-92. PubMed ID: 28038867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [¹²³I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism.
    Tinazzi M; Cipriani A; Matinella A; Cannas A; Solla P; Nicoletti A; Zappia M; Morgante L; Morgante F; Pacchetti C; Sciarretta M; Dallocchio C; Rossi S; Malentacchi M; Ceravolo R; Frosini D; Sestini S; Bovi T; Barbui C
    Schizophr Res; 2012 Aug; 139(1-3):40-5. PubMed ID: 22727453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism.
    Mateos JJ; Lomeña F; Parellada E; Font M; Fernandez E; Pavia J; Prats A; Pons F; Bernardo M
    Psychopharmacology (Berl); 2005 Sep; 181(2):401-6. PubMed ID: 15830229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative evaluation of striatal I-123-FP-CIT uptake in essential tremor and parkinsonism.
    Cuberas-Borrós G; Lorenzo-Bosquet C; Aguadé-Bruix S; Hernández-Vara J; Pifarré-Montaner P; Miquel F; Álvarez-Sabin J; Castell-Conesa J
    Clin Nucl Med; 2011 Nov; 36(11):991-6. PubMed ID: 21975386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FP-CIT SPECT in clinically inconclusive Parkinsonian syndrome during amiodarone treatment: a study with follow-up.
    Hambÿe AS; Vervaet A; Dethy S
    Nucl Med Commun; 2010 Jun; 31(6):583-9. PubMed ID: 20429096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of an automated morphological MRI-based (123)I-FP-CIT SPECT evaluation method.
    Perlaki G; Szekeres S; Orsi G; Papp L; Suha B; Nagy SA; Doczi T; Janszky J; Zambo K; Kovacs N
    Parkinsonism Relat Disord; 2016 Aug; 29():24-9. PubMed ID: 27290659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease.
    Diaz-Corrales FJ; Sanz-Viedma S; Garcia-Solis D; Escobar-Delgado T; Mir P
    Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):556-64. PubMed ID: 19862520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes.
    Hauser RA; Grosset DG
    J Neuroimaging; 2012 Jul; 22(3):225-30. PubMed ID: 21410815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease.
    Zijlmans J; Evans A; Fontes F; Katzenschlager R; Gacinovic S; Lees AJ; Costa D
    Mov Disord; 2007 Jul; 22(9):1278-85. PubMed ID: 17486613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease.
    Ottaviani S; Tinazzi M; Pasquin I; Nothdurfter W; Tomelleri G; Fincati E; Nordera G; Moretto G; Fiaschi A; Smania N; Giorgetti P; Antonini A
    Neurol Sci; 2006 Dec; 27(6):397-401. PubMed ID: 17205224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal evaluation using FP-CIT in patients with parkinsonism.
    Martínez-Valle Torres MD; Ortega Lozano SJ; Gómez Heredia MJ; Amrani Raissouni T; Ramos Moreno E; Moya Espinosa P; Jiménez-Hoyuela JM
    Neurologia; 2014; 29(6):327-33. PubMed ID: 24139386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group.
    Benamer TS; Patterson J; Grosset DG; Booij J; de Bruin K; van Royen E; Speelman JD; Horstink MH; Sips HJ; Dierckx RA; Versijpt J; Decoo D; Van Der Linden C; Hadley DM; Doder M; Lees AJ; Costa DC; Gacinovic S; Oertel WH; Pogarell O; Hoeffken H; Joseph K; Tatsch K; Schwarz J; Ries V
    Mov Disord; 2000 May; 15(3):503-10. PubMed ID: 10830416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.
    Kuya K; Shinohara Y; Miyoshi F; Fujii S; Tanabe Y; Ogawa T
    Neuroradiology; 2016 Apr; 58(4):351-6. PubMed ID: 26779912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.